Beijing CRO expands agreement with Merck KGaA; Early-stage venture firm closes its first fund
On Thursday morning, Beijing-based CRO Biocytogen announced that it has formalized and expanded its April agreement with Merck KGaA following an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
